MedWatch

Eli Lilly lowers guidance for 2021

In spite of its growing revenue and positive Trulicity sales, Eli Lilly has opted to lower its 2021 guidance, according to the firm's quarterly report for the first three months of the year.

Photo: Mike Blake/Reuters/Ritzau Scanpix

US pharmaceutical company Eli Lilly lowers its upper estimate for this year's income in connection with the publication of its quarterly report on Tuesday.

The US pharmaceutical company now expects to earn between USD 7.80-8.00 per share for 2021, while the previous estimate was USD 7.75-8.40.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

In a world of options, Genmab's CEO chose partnerships

In 2015, Genmab partnered with relatively unknown biotech firm Biontech. Reflecting on how far Genmab has come since, CEO Jan van de Winkel is still confident that partnerships, rather than acquisitions, are the way forward. If it had acquired Biontech at the time, the CEO speculates Genmab may have put a stop to other activities – including the Covid-19 vaccine efforts that went on to save millions of lives. This and fairness are worth remembering as biotech firms are increasingly strapped for cash, van de Winkel reflects.

Analyst predicts slow start for Leo Pharma's Adtralza in UK

The take-up of Leo Pharma’s atopic eczema drug Adtralza in the UK will be slow-going, according to analyst bureau Global Data, after the British institute NICE released draft guidance where it was not recommend it as a standard treatment in England and Wales.

Further reading

Related articles

Latest news

See all jobs